Cadence Pharmaceuticals Reports Third Quarter 2009 Financi...(expense) income net (145979)...),Health

Date:11/5/2009

expense) income, net (145,979) (88,336) (742,411) (71,653) -------- ------- -------- ------- Net loss $(11,441,105) $(13,748,995) $(30,178,549) $(43,062,746) ============ ============ ============ ============ Basic and diluted net loss per share(1) $(0.23) $(0.36) $(0.63) $(1.18) ====== ====== ====== ====== Shares used to compute basic and diluted net loss per share(1) 50,364,493 38,116,063 48,189,177 36,371,272 ========== ========== ========== ========== (1) As a result of the issuance of 12,039,794 shares of common stock pursuant to a private placement in the first quarter of 2009 and 9,240,307 shares of common stock pursuant to an effective shelf registration in the first quarter of 2008, there is a lack of comparability in the per share amounts between the 2009 and 2008 periods presented.

                           CADENCE PHARMACEUTICALS, INC.
                           (a development stage company)
                             CONDENSED BALANCE SHEETS

                                                   September 30,  December 31,
                                                       2009           2008
                                                       ----           ----
                                                    (unaudited)
                     Assets
    Current assets:
      Cash, cash equivalents and short-term
       investments                                   $96,552,282  $47,627,246
      Restricted cash                                  1,695,696    2,195,696
      Prepaid expenses and other current assets          569,427      219,674
                                                         -------    
'/>"/>
SOURCE  Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 
Related medicine news :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
3. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
4. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
9. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery